Filing Details
- Accession Number:
- 0001232524-17-000073
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-03-08 17:39:38
- Reporting Period:
- 2017-03-06
- Filing Date:
- 2017-03-08
- Accepted Time:
- 2017-03-08 17:39:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1232524 | Jazz Pharmaceuticals Plc | JAZZ | Pharmaceutical Preparations (2834) | 981032470 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1615763 | Paul Treacy | Connaught House, 1 Burlington Rd, Fl. 4 Dublin 4 L2 | Svp, Technical Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Disposition | 2017-03-06 | 355 | $131.97 | 18,108 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2017-03-06 | 529 | $131.97 | 17,579 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $131.4935 to $131.9800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes toprovide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $131.5330 to $131.9800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes toprovide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Billionaire Hedge Funds
